Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Adaptation of the right ventricle is a key determinant of outcomes in pulmonary arterial hypertension (PAH). Despite a compelling rationale to develop targeted therapies for the right ventricle in PAH, no such treatments exist. H-receptor antagonism is a potential myocardial-focused paradigm in heart failure.
Research Question: Do H-receptor antagonists improve outcomes in patients with PAH?
Study Design And Methods: We conducted a 24-week, single-center, 1:1 randomized, double-masked, placebo-controlled trial of the H-receptor antagonist famotidine in patients with a diagnosis of PAH. The primary outcome was change in 6-minute walk distance (6MWD) at 24 weeks. Secondary end points included B-type natriuretic peptide levels, New York Heart Association functional class, right ventricular parameters measured from echocardiography, health-related quality of life, and escalation in PAH-focused care.
Results: From May 2019 through July 2023, 80 participants were randomized with 79 receiving study drug. No significant difference in the primary outcome of 6MWD at 24 weeks was found, with an increase of 4.7 m seen in the placebo arm vs a decrease of 17.0 m in the famotidine arm (P = .24). Also no differences were found in secondary end points at 24 weeks. Study drug was well tolerated, and safety profiles were similar between arms. Adherence and study conduct were good overall. Participants with methamphetamine-associated PAH were similar in all aspects to the study participants more broadly.
Interpretation: The results of this trial do not support the routine use of famotidine 20 mg daily as an adjunct therapy for the treatment of PAH. The findings of the Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension (REHAB-PH) trial argue against the practice of avoiding participants with methamphetamine-associated PAH in randomized clinical trials of novel therapies.
Clinical Trial Registry: ClinicalTrials.gov; No.: NCT03554291; URL: www.
Clinicaltrials: gov.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12264346 | PMC |
| http://dx.doi.org/10.1016/j.chest.2024.12.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors influencing diagnostic yield and complication risk in computed tomography fluoroscopy-guided lung biopsies: a 10-year single-center study.
Diagn Interv Radiol
September 2025
LMU University Hospital, LMU Munich, Department of Radiology, Munich, Germany.
Purpose: Computed tomography fluoroscopy (CTF)-guided biopsy is an established technique for sampling pulmonary lesions, particularly with the growing prevalence of lung nodule screening programs. This study investigated procedural and lesion-related factors affecting success and complication rates in routine CTF-guided lung core-needle biopsies at a tertiary center.
Methods: Consecutive patients undergoing percutaneous CTF-guided lung biopsies over a 10-year period (2007-2016) were retrospectively analyzed.
Background: Advancements in healthcare have significantly improved the prospect of patients with CHD, with over 97% now surviving adulthood. This growing population requires lifelong care and support to manage their condition. Digital health innovations, such as the "Ask Me Anything" (AMA) tool, aim to empower patients and improve collaboration with clinicians.
View Article and Find Full Text PDF[One-year clinical results of the Multidisciplinary Consultation at the Emphysema Clinic of CHU Liege].
Rev Med Liege
September 2025
Service de Pneumologie, CHU Liège, Belgique.
Severe emphysema impairs lung function and quality of life in patients with Chronic Obstructive Pulmonary Disease (COPD). Despite optimized medical treatment and rehabilitation, some patients require lung volume reduction interventions (endoscopic or surgical). This study evaluates one-year outcomes of patients managed at the Emphysema Clinic of CHU Liège.
View Article and Find Full Text PDF[Traumatic pulmonary pseudocyst].
Rev Med Liege
September 2025
Service des Urgences, CHC MontLégia, Liège, Belgique.
Traumatic pulmonary pseudocysts (TPPs) are rare but clinically relevant complications of thoracic trauma, often misdiagnosed due to their non-specific presentation and resemblance to other cavitary pulmonary lesions. We report the case of a 26-year-old male presenting with delayed symptoms following a fall, ultimately diagnosed with multiple TPPs via thoracic CT scan. The patient experienced a favourable evolution with conservative management, including aerosolized tranexamic acid for minor hemoptysis.
View Article and Find Full Text PDFPrognostic values and clinical significance of POU2F3 expression in neuroendocrine carcinomas: a meta-analysis with a focus on small cell lung cancer.
Ann Med
December 2025
Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Background: Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine carcinoma (NEC) with poor prognosis due to chemotherapy resistance. Molecular subtypes, including ASCL1, NEUROD1, YAP1 and POU2F3, have distinct clinical implications. POU2F3, linked to a tuft cell-like lineage, represents a non-neuroendocrine subtype found in SCLC and extrapulmonary NECs.
View Article and Find Full Text PDF